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Essentials
• The immunogenesis of Heparin-induced thrombocytopenia (HIT) is not well understood.
• Immunization to platelet factor 4 (PF4)-heparin occurs early in life, before any heparin exposure.
• PF4 and PF4-heparin complexes induce the proliferation of CD14 + cells.
• Reduced levels of regulatory cytokines contribute to immune dysregulation in HIT.
Summary. Background: Heparin-induced thrombocytopenia (HIT) is an adverse reaction to heparin characterized by thrombocytopenia and thrombotic complications. HIT is caused by pathogenic antibodies that bind to complexes of platelet factor 4 (PF4) and heparin, leading to platelet activation and inducing a hypercoagulable state. Previous studies have shown immunity to PF4-heparin complexes occurs early in life, even before heparin exposure; however, the immunogenesis of HIT is not well characterized. Objectives: To investigate cellular proliferation in response to PF4-heparin complexes in patients with HIT. Patients/Methods: Peripheral blood mononuclear cells (PBMCs) from healthy controls (n = 30), postoperative cardiac surgery patients who had undergone cardiopulmonary bypass (CPB) (n = 17) and patients with confirmed HIT (n = 41) were cultured with PF4 and PF4-heparin complexes. Cellular proliferation was assessed by [ 3 H]thymidine uptake and 5-ethynyl-2 0 -deoxyuridine detection. Results and Conclusions: PBMCs proliferated in the presence of PF4, and this was enhanced by the addition of heparin in all study groups. CPB and HIT patients showed significantly greater proliferative responses than healthy controls. PBMC proliferation was antigenspecific, depended on the presence of platelets, and only CD14 + cells were identified as proliferating cells. Culture supernatants were tested for the levels of regulatory cytokines, and both CPB and HIT patients produced significantly lower levels of interleukin-10 and transforming growth factor-b1 than healthy controls. These findings further
Introduction
Heparin is widely used for the prevention of thrombotic events during orthopedic and cardiac surgery [1] . Approximately 1-5% of patients exposed to unfractionated heparin develop a life-threatening prothrombotic immune reaction, known as heparin-induced thrombocytopenia (HIT) [2] [3] [4] [5] . In HIT, heparin binds platelet factor 4 (PF4) to form PF4-heparin complexes and expose neoantigens [6] [7] [8] that bind IgG-specific autoantibodies, causing platelet activation with a heightened risk of thrombosis [8] [9] [10] [11] .
The immune response in HIT is atypical: (i) anti-PF4-heparin IgG antibodies are produced at the same time as IgM and IgA, as early as 5 days after heparin exposure [12] ; (ii) anti-PF4-heparin antibodies become undetectable 3 months after heparin administration [13, 14] ; and (iii) repeated heparin exposure does not usually elicit HIT recurrence, implying a lack of immune memory [15, 16] . Both T-cell-dependent and T-cell-independent immune mechanisms are probably important in HIT [17] . Previous studies have shown HIT patients possess T cells with PF4-heparin-specific T-cell receptors [18, 19] , and murine models have demonstrated CD4 + T cells are necessary for the production of anti-PF4-heparin antibodies [20, 21] . However, marginal zone B cells and B1 cells, which can produce antibodies independently of T cells, have also been implicated in HIT [22, 23] .
Immune sensitization to PF4 complexed with naturally occurring glycosaminoglycans can occur prior to heparin exposure [24] . This model of immune sensitization has been demonstrated by studies reporting PF4 binding to bacterial surfaces are capable of binding anti-PF4-heparin antibodies [24] [25] [26] . In addition, some healthy individuals exposed to heparin in the absence of surgery also produce anti-PF4-heparin antibodies [27] . Zheng et al. used a murine model to demonstrate an important role for immune dysregulation in HIT [28] . Collectively, these findings suggest exposure to structurally modified immunogenic PF4 throughout an individual's life may lead to HIT upon exposure to heparin.
In this study, we showed peripheral blood mononuclear cells (PBMCs) from healthy controls, postoperative cardiac surgery patients requiring cardiopulmonary bypass (CPB) and HIT patients possess pre-existing immune cells are responsive to PF4 and PF4-heparin complexes. The levels of regulatory cytokines were also found to be reduced in cell cultures of CPB and HIT patients, providing further evidence of immune dysregulation in HIT.
Materials and methods

Patients
Participants included healthy controls (n = 30), patients exposed to heparin during cardiac surgery with CPB (n = 17), and patients diagnosed with HIT (n = 41). Peripheral blood from CPB patients was collected at a median 5.6 days (range: 3-10 days), as up to 70% of CPB patients produce anti-PF4-heparin antibodies [29, 30] . HIT diagnosis was confirmed by use of the 4Ts score, a positive in-house PF4-heparin-dependent IgGspecific enzyme immunoassay (EIA) result (OD ≥ 0.45) [31] , and a positive heparin-dependent serotonin-release assay (SRA) result (≥ 20% [ 14 C]serotonin release) [32] . Peripheral blood from HIT patients was collected at a median 17.7 days (range: 9-29 days) after heparin administration. PBMCs from all study groups were freshly isolated and cultured on the day of the blood draw. This study was approved by the Hamilton Integrated Research Ethics Board, and informed written consent was obtained from all participants.
PF4 purification
PF4 was purified as previously described [33] , analyzed by HPLC (Beckman-Coulter, Pasadena, CA, USA) with a Jupiter 5u C4 150 9 10.0-mm reverse-phase column (Phenomenex, Torrance, CA, USA), and filtered with an Acrodisc syringe filter with Mustang E membrane (Pall, Port Washington, NY, USA). The Limulus amebocyte lysate chromogenic endotoxin detection assay (Pierce, Rockford, IL, USA) confirmed endotoxin levels to be < 0.1 EU mL À1 (0.01 ng mL À1 ). The antigenic and functional reactivities of purified PF4 were determined with the PF4-heparin EIA and the PF4 SRA, respectively [31, 34] .
Antigen-induced PBMC proliferation
In preliminary experiments, optimal concentrations of PF4 and heparin were determined. PBMCs (1 9 10 5 in 100 lL) from peripheral blood (90 mL) were layered over Histopaque-1077 (Sigma-Aldrich, St Louis, MO, USA) and separated by density gradient centrifugation at 400 9 g for 30 min. After washing, PBMCs were added to 96-well plates (BD Falcon, Bedford, MA, USA) with varying amounts of PF4 (0, 12. To investigate the role of platelets, which are unable to proliferate, 15-20 9 10 6 PBMCs of healthy controls (n = 4) were depleted of platelets by centrifugation at 250 9 g for 10 min, and the platelet-rich supernatant was aspirated. Platelet-depleted PBMCs and PBMCs reconstituted with platelets to their initial concentration were then cultured with PF4 and PF4-heparin, and assessed for [ PBMCs (1 9 10 5 in 100 lL) were seeded with antigen or medium alone in 12 replicates. On day 6, PBMCs were pulsed with 10 mM 5-ethynyl-2 0 -deoxyuridine (Click-IT EdU; ThermoFisher Scientific, Waltham, MA, USA) and incubated for 16-18 h in 5% CO 2 at 37°C. On day 7, cells were collected and stained with fluorescently labeled cell surface markers: anti-human CD4-fluorescein isothiocyanate, CD8-Allophycocyanin-eFluor 780, anti-human CD14-peridinin chlorophyll-Cyanine5.5, and anti-human CD19-phycoerythrin (eBioscience, San Diego, CA, USA), or their isotype equivalents. After washing, cells were fixed and permeabilized to label incorporated EdU with a fluorophore (Alexa647), according to the manufacturer's instructions. Cells were then analyzed with flow cytometry by collecting a minimum of 50 000 events with a Beckman Coulter CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA), and analyses were performed with FLOWJO version 10.1R5 (Tree Star, Ashland, OR, USA). Leukocyte subpopulations were defined by side scatter and forward scatter characteristics, and gated populations were identified for EdU uptake on the x-axis, and for cell surface markers for T cells (CD4 and CD8), B cells (CD19) and monocytes (CD14) on the y-axis. Data were reported as the percentage of proliferating cells.
Identification of proliferating cells in PBMC cultures using fluorescence microscopy
Isolated PBMCs were cultured with PF4-heparin or medium alone, and pulsed with EdU similar to the flow cytometry experiments previously mentioned; however, on day 7, cells were labeled with 20 lg mL À1 unconjugated antihuman CD14 (clone 61D3; eBioscience) followed by 8 lg mL À1 Alexa Fluor 488 goat anti-human IgG (H + L;
Life Technologies, Carlsbad, CA, USA). Cells were then fixed, permeabilized, and stained with a fluorophore (Alexa647) specific for EdU, according to the manufacturer's instructions. Then, cells were centrifuged onto a glass slide with a Shandon Cytospin 3 (ThermoFisher Scientific) at 300 r.p.m., for 5 min, and Prolong Gold anti-fade reagent with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Life Technologies) was added with a coverslip. Cells were imaged with the EVOS FL Auto-microscope equipped with a 920 plan apochromat objective with a numerical aperture of 0.75 (Life Technologies).
Cytokine measurement
PBMCs (1.25 9 10 6 cells) from healthy controls (n = 9), CPB patients (n = 9) and HIT patients (n = 10) were added to each well of a 48-well plate (Costar, Corning, NY, USA) in the presence of PF4-heparin or with AIM-V medium alone, and incubated for 5 days at 37°C in 5% CO 2 . Luminex bead-based multianalyte profiling (Bio-Rad) was used to simultaneously measure the following cytokines: IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, interferon (IFN)-c, transforming growth factor (TGF)-b1, tumor necrosis factor (TNF)-a, and RANTES. Fifty microliters of diluted standard or cytokine supernatant was added to color-coded polystyrene beads precoated with the aforementioned analyte-specific capture antibodies in duplicate, according to the manufacturer's instructions. The beads were then measured with a CS1000 Autoplex analyzer (Bio-Rad).
Statistical analysis
A Shapiro-Wilk test of normality showed that all proliferation and cytokine datasets were non-normally distributed. Hence, non-parametric statistical tests were used to compare groups (i.e. Mann-Whitney U-test). Geometric means AE 95% confidence intervals (CIs) were calculated for proliferation and cytokine data sets, owing to the skewness of the distributions. Parametric tests (i.e. unpaired Student's t-test) were used to compare proliferation in healthy controls with PF4, PF4-heparin, and PF4-fondaparinux, and for the percentage of CD14 + proliferating cells for all study groups, with data presented as the mean SI AE standard error of the mean. Correlational statistics were completed by use of a Spearman rank correlation coefficient. Data were analyzed with GRAPHPAD PRISM version 6.0 (GraphPad Software, La Jolla, CA, USA). A P-value of < 0.05 was considered to be statistically significant.
Results
Patient demographics
The median age of healthy controls (n = 30) was 34.3 years (range: 19.2-60.6 years), and 16 (53.3%) were female ( Table 1 ). All healthy controls denied previous heparin exposure.
The median age of CPB patients (n = 17) was 68.2 years (range: 52.2-76.7 years), and four (28.6%) were female ( PBMC proliferation in response to PF4, PF4-heparin and PF4-fondaparinux in healthy controls PBMC proliferation in response to various concentrations of PF4 and unfractionated heparin was antigen-specific and dependent on specific ratios of PF4 and heparin (Fig. 1A,B 0.99 AE 0.067; P = 0.046; Fig. 1B ), and no proliferation was observed with heparin alone. The ability of PBMCs to proliferate in response to PF4-fondaparinux was also tested, and was found to be similar to that with heparin, but at an approximately five-fold higher concentration. Proliferation was optimal at 1.56 U mL À1 fondaparinux vs. 0.25 U mL À1 heparin, and proliferation was inhibited at 12.5 U mL À1 vs. 2.5 U mL À1 (Fig. 1C) . To ensure that
proliferation was consistent, we tested healthy controls (n = 7) at three different time points (at least 1 month and up to 6 years apart), and did not observe any significant variability (data not shown). Digested PF4 was unable to induce PBMC proliferation (SI: without heparin, 0.64; with heparin, 0.60), in contrast to intact PF4 (SI: without heparin, 9.2; with heparin, 12.5 ( Fig. 2A,B) . Taken together, our findings demonstrated PBMC proliferation required intact PF4, and was not attributable to endotoxin or additional confounding factors.
To determine whether proliferation was PF4-specific and not attributable to a cationic heparin-binding protein, we examined whether protamine sulfate and protamine sulfate-heparin complexes were able to induce PBMC proliferation, by using healthy controls (n = 3). No significant proliferation was observed with protamine sulfate alone (SI: 0.38 AE 0.036) or when it was combined with heparin (SI: 0.28 AE 0.017).
PF4-induced PBMC proliferation in postoperative cardiac surgery patients and patients with HIT PBMC proliferation was observed with PF4 and enhanced by heparin in all study groups: healthy controls (n = 30), CPB patients (n = 17), and HIT patients (n = 41) (Fig 3A,  B) . As compared with PBMCs from healthy controls, those from CPB patients showed significantly elevated proliferation with PF4 (6.15 3 H]thymidine in cultures incubated with PF4, PF4-heparin and PF4-fondaparinux relative to medium alone, and data represent the mean AE standard error of the mean for each condition. PF4 increased proliferation and heparin enhanced PBMC proliferation optimally at 0.25 U mL À1 and inhibited proliferation at 2.5 U mL
À1
. Similarly, fondaparinux enhanced PBMC proliferation optimally at 1.56 U mL À1 and inhibited proliferation at 12.5 U mL À1 . 
Contribution of platelets to PF4-induced and PF4-heparininduced proliferation
To investigate the role of platelets in mediating PF4-dependent and PF4-heparin-dependent PBMC proliferation, PBMCs from healthy controls (n = 4) with a mean starting platelet count of 279 9 10 9 L À1 (range: 225-320 9 10 9 L À1 ) were depleted of platelets to a mean platelet count of 32 9 10 9 L À1 (range: 3-52 9 10 9 L
À1
). Removal of platelets from PBMCs resulted in significant reductions in the levels of PBMC proliferation induced by PF4 (8.38% AE 1.06% vs. 2.41% AE 0.83%; P = 0.0044) and by PF4-heparin (19.38% AE 3.97% vs. 5.25% AE 1.65%; P = 0.017) as compared with PBMC cultures containing platelets. After platelet-depleted PBMCs were reconstituted with platelets, proliferation was restored when they were cultured with PF4 (7.450% AE 2.246%) and PF4-heparin (10.98% AE 1.724%) (Fig. 4A,B) .
Identification of specific immune cells proliferating in response to PF4 and PF4-heparin
PBMCs from healthy controls (n = 2), CPB patients (n = 3) and HIT patients (n = 3) were cultured in the presence of PF4, PF4-heparin, R848 and IL-2, or medium alone, to determine which PBMCs were responsible for the proliferation signal. Only CD14 + cells were shown to proliferate, no proliferation was observed with CD4 + and CD8 + T cells and CD19 + B cells (Fig. 5A) . The percentage of CD14 + cells proliferating for all subjects, as measured by EdU uptake, is also shown (Fig. 5B) . Among healthy controls (n = 2), the percentage of CD14 + cells proliferating in response to PF4 was 5.90% AE 3.90%, the percentage of CD14 + cells proliferating in response to PF4-heparin was 9.81% AE 4.76%, and the percentage of CD14 + cells proliferating in medium alone was 1.99% AE 0.32%. Among CPB patients (n = 3), the percentage of CD14 + cells proliferating in response to PF4 was 11.72% AE 4.12%, the percentage of CD14 + cells proliferating in response to PF4-heparin was 15.09% AE 4.36%, and the percentage of CD14 + cells proliferating in medium alone was 1.49% AE 0.11%. The percentage of CD14 + cells proliferating in response to PF4-heparin was found to be significantly higher than the percentage of CD14 + cells proliferating in medium alone (P = 0.036). Among HIT patients (n = 3), the percentage of CD14 + cells proliferating in response to PF4 was 6.65% AE 4.11%, the percentage of CD14 + cells proliferating in response to PF4-heparin was 11.32% 4.11%, and the percentage of CD14 + cells proliferating in medium alone was 3.27% AE 1.53%. The morphology of PBMCs cultured with PF4-heparin was visualized with EdU-labeled nuclear DNA in the S-phase (red), anti-CD14 (green), and DAPI (blue). A representative image of three independent experiments is shown (Fig. 5C ).
IL-10 and TGF-b1 produced by PBMCs from cardiac surgical patients and HIT patients
In order to further investigate the immune response to PF4 and PF4-heparin, the cytokine profile levels for IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, IFN-c, TGF-b1, TNF-a, TGF-b1, and RANTES were examined. No statistical differences were seen between study groups for the aforementioned cytokines (data not shown), with the exception of IL-10 and TGF-b1 (Fig. 6A,B) . PBMCs from CPB patients (n = 9) stimulated with PF4-heparin showed significantly reduced levels of IL-10 ( 
Discussion
The presence and nature of antibodies in HIT have been well described; however, the cellular immune response is not well characterized. In this study, PBMCs from CPB and HIT patients showed significantly higher cellular proliferation in response to PF4 and PF4-heparin than PBMCs from healthy controls. In all study groups, CD14 + cells were responsible for the proliferation signal. We also demonstrated that PBMCs from CPB and HIT patients secrete lower levels of the regulatory cytokines IL-10 and TGF-b1. Taken together, these findings suggest that immune regulation is attenuated in both CPB patients HIT patients.
PBMCs proliferated in the presence of PF4 at variable levels in all study groups. This proliferation response was enhanced by heparin and inhibited by high-dose heparin, which is consistent with the effects of heparin in diagnostic HIT assays. We found that fondaparinux also enhanced the proliferative response when complexed with PF4, consistent with previous observations showing PF4-fondaparinux complexes are immunogenic, but rarely antigenic [36, 37] .
The cellular immune proliferative response to PF4 and PF4-heparin was shown to be antigen-specific, suggesting healthy controls possess immune cells sensitized to PF4-heparin even before exposure to heparin. Our data are consistent with the findings of Prechel and Walenga, showing that specific PF4-heparin complexes elicited a Toll-like receptor 4-mediated response at the same PF4/ heparin molar ratio of 12.5 : 1 used in our study [38] . In addition, Joglekar et al. showed that the uptake of PF4 by monocytes and macrophages from healthy controls was enhanced by heparin at a similar molar ratio [39] .
We demonstrated protamine sulfate, which is associated with an HIT-like disorder known as protamine-induced thrombocytopenia [40] , is unable to elicit proliferation. The ability of antigen-presenting cells to phagocytose PF4-heparin complexes can be mimicked by protamineheparin complexes [39] , which are unable to induce proliferation of isolated T cells [41] . The results of Joglekar et al. and of our study indicate that, although heparinbinding proteins, such as protamine and PF4, can be phagocytosed by monocytes, the proliferative responses are probably specific to PF4-heparin.
This study also showed platelets are required for proliferation in response to PF4 and PF4-heparin, either directly or through platelet-derived cytokine release. This finding is consistent with the known properties of platelets, which have been shown to enhance the differentiation and cytokine production of effector and regulatory T cells [42, 43] . When PBMCs were stimulated with PF4 or PF4-heparin, only CD14 PF4-heparin relative to medium alone, and data represent the mean AE standard error of the mean for each condition. The results show that there was a significant decrease in proliferative responses when the PBMC preparations were depleted of platelets. In cultures incubated with PF4, PBMC proliferation (8.38% AE 1.06%) decreased when the cultures were depleted of platelets (2.41% AE 0.83%; P = 0.0044). Proliferation was restored when platelet-depleted PBMCs were reconstituted with platelets (7.450% AE 2.246%). In cultures incubated with PF4-heparin, PBMC proliferation (19.38% AE 3.97%) also decreased when the cultures were depleted of platelets (5.25% AE 1.65%; P = 0.017) and increased when platelet-depleted PBMCs were reconstituted with platelets (10.98% AE 1.724%). PBMCs were isolated from healthy controls (n = 2), cardiopulmonary bypass (CPB) patients (n = 3), and heparin-induced thrombocytopenia (HIT) patients (n = 3), and cultured in the presence of PF4, PF4-heparin, or medium alone. PBMCs were pulsed with 5-ethynyl-2 0 -deoxyuridine (EdU), collected on day 7, and stained with fluorescently labeled cell surface markers: anti-human CD4-fluorescein isothiocyanate, antihuman CD8-allophycocyanin-efluor 780, anti-human CD14-peridinin chlorophyll-Cyanine5.5, and anti-human CD19-phycoerythrin, or their isotype equivalents. Leukocyte subpopulations were defined by side scatter and forward scatter characteristics, and gated populations were identified for EdU uptake on the x-axis and for cell surface markers for T cells (CD4 and CD8), B cells (CD19) and monocytes (CD14) on the y-axis for each antigen. + T cells or CD19 + B cells. CD14 + proliferation was found in all three study groups, although proliferation was higher in CPB and HIT patients than in healthy controls. Previous studies using murine immunization models have supported a role for T cells and B cells the responses to PF4 and heparin [20] [21] [22] [23] 39, [44] [45] [46] [47] . Consistent with our findings, monocytes have been shown to survive and differentiate into macrophages and dendritic cells when cultured with PF4 [45] [46] [47] [48] . In addition, monocytes have been shown to bind and internalize PF4 and PF4-heparin complexes, resulting in the cellular activation of monocytes [39, 49] .
Our data also demonstrated a significant reduction in the levels of the regulatory cytokines IL-10 and TGF-b1 in CPB and HIT patients. IL-10 and TGF-b1 levels did not differ significantly among CPB and HIT patients, which suggests a role for iatrogenic inflammation in the immunogenesis of HIT. Indeed, higher levels of PF4 and heparin in patients undergoing CPB support the notion that permissive conditions during surgery are associated with the development of HIT [1, 8, 49] . The IL-10 finding is consistent with a previous study by Pouplard et al., in which IL-10 promoter microsatellite polymorphisms were found to be associated with PF4-heparin antibody production in both CPB and HIT patients [50] . Collectively, the findings of Pouplard et al. and of our study suggest that IL-10 plays an important role in the protection against the development of PF4-heparin antibodies in patients treated with heparin [50] . IL-10, which is produced by many lymphocytes, is known to inhibit both innate and adaptive immune responses, and is commonly regarded as a potent immunosuppressive cytokine [51] . IL-10 can also inhibit the production of proinflammatory cytokines and suppress antigen presentation and cellular proliferation [51] . Similarly, TGF-b has the ability to strongly suppress lymphocyte proliferation, and is also produced by almost every activated lymphocyte, with the highest amounts being found in human platelets and mammalian bone [52, 53] . Low levels of IL-10 and TGF-b are also implicated in other autoimmune disorders, such as inflammatory bowel disease, psoriasis, and systemic lupus erythematosus, owing to the loss of immune regulation [54] [55] [56] [57] .
A limitation of this study is the lack of mechanistic investigations into the potential role of other immune cells in supporting the observed proliferation of CD14 + cells. In addition, the cellular microenvironment generated following CPB surgery and in the presence of HIT might have impacted on proliferative responses. Although we demonstrated cellular proliferation of CD14 + cells following stimulation with PF4-heparin, further studies are needed to determine a specific role in the immunobiology of HIT.
To our knowledge, this is the first study to investigate the cellular immune response and immune dysregulation in a large cohort of patients with active HIT. This study showed increased PBMC proliferation in response to PF4 and PF4-heparin in CPB and HIT patients with lower levels of IL-10 and TGF-b1 as compared with healthy controls, suggesting immune dysregulation could be central in the immunogenesis of HIT.
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